CBS up +1.40% percent Today $CBS High is at 52.30 and the

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
CBS up +1.40% percent Today $CBS High is at 52.30 and the Low 51.63 with current volume of 523,240.

Recent News posted below.

CBS Corp CBS other info.
http://investorshangout.com/CBS-Corp-CBS-50453/

CBS CBS Corp Recent Headline News

CBS Corporation To Report Fourth Quarter And Full Year 2014 Results On Thursday, February 12
PR Newswire - 1 hr 15 mins ago
CBS Corporation (NYSE: CBS.A and CBS) announced today that it will report results for the fourth quarter and full year of 2014 after the market closes on Thursday, February 12, 2015. The earnings announcement will be available in the Investors/News & Events section of the Company's corporate web site, www.cbscorporation.com.
CBS: 52.02 (+0.45)

CBS Films and Lions Gate hammer out distribution deal
Seeking Alpha - at Seeking Alpha - 2 hrs 51 mins ago

LGF: 35.25 (+0.86), CBS: 52.02 (+0.45)

Viacom Beats Q4 Earnings on Theater Revenue Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 9:12AM CST
Viacom Inc. (VIAB) declared fourth-quarter fiscal 2014 financial results wherein both the top and the bottom line surpassed the corresponding Zacks Consensus Estimate.
VIAB: 72.03 (+2.78), CBS: 52.02 (+0.45), NWSA: 15.04 (-0.23), TWX: 78.50 (+0.82)


Victim's family doesn't want CBS to air segment
By DAVID BAUDER - AP - Thu Nov 13, 6:11AM CST
NEW YORK (AP) — The family of a woman murdered while vacationing in Mexico wants CBS not to air a prison diary made by the man accused of the crime for fear it will make him a sympathetic figure.
CBS.A: 52.50 (+0.70), CBS: 52.02 (+0.45)

Showtime Has a Lot to Gain by Going a la Carte
Adam Levy, The Motley Fool - Motley Fool - Wed Nov 12, 6:22PM CST
Showtime may soon be available without a cable subscription. Source: Sho.com Following in the footsteps of Time Warner and HBO, CBS plans to offer Showtime without a cable subscription. Speaking on the company's third-quarter earnings call...
NFLX: 378.15 (-5.71), TWX: 78.50 (+0.82), CBS: 52.02 (+0.45)

Stark warning sounded on TV stocks
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 9:49AM CST

PBS: 24.90 (+0.05), VIA: 72.43 (+2.90), DISCA: 32.49 (+0.63), VIAB: 72.03 (+2.78), SNI: 73.21 (-0.29), CBS: 52.02 (+0.45)

'Mad Money' Lightning Round: Avoid LyondellBasell Industries, Go for Dow Chemical
at The Street - Wed Nov 12, 5:00AM CST
In Tuesday's Lightning Round, Cramer said Adobe is a great idea with consistent earnings.
T: 35.62 (+0.22), CY: 9.93 (-0.21), LYB: 87.00 (-1.59), KEX: 104.78 (-1.47), LRN: 12.37 (-0.44), VZ: 50.87 (+0.05), DOW: 49.20 (-0.70), GTLS: 44.09 (-2.16), ADBE: 71.37 (-0.04), CBS: 52.02 (+0.45)

Cramer's Lightning Round - Chart Industries Is In No Man's Land (11/11/14)
SA Editor Miriam Metzinger - Seeking Alpha - Wed Nov 12, 4:34AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday November 11. Bullish Calls: Cypress Semiconductor (NASDAQ: CY ): "I like it. It is doing a spinoff that is going to be worth as much as CY....
T: 35.62 (+0.22), CY: 9.93 (-0.21), LYB: 87.00 (-1.59), KEX: 104.78 (-1.47), LRN: 12.37 (-0.44), DOW: 49.20 (-0.70), VZ: 50.87 (+0.05), GTLS: 44.09 (-2.16), ADBE: 71.37 (-0.04), CBS: 52.02 (+0.45), TWX: 78.50 (+0.82)

Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names
at The Street - Tue Nov 11, 7:59PM CST
Cramer says record-low interest rates seem to have finally paid off for the home builders. That means good things for the folks who make interior items, too.
DHI: 24.27 (+0.26), TSLA: 252.70 (+3.60), AMZN: 314.63 (+3.12), CY: 9.93 (-0.21), XOM: 94.21 (-1.17), KEX: 104.78 (-1.47), LRN: 12.37 (-0.44), BWLD: 162.50 (-0.50), ADBE: 71.37 (-0.04), GTLS: 44.09 (-2.16), TWX: 78.50 (+0.82), WHR: 175.18 (-0.03), T: 35.62 (+0.22), LYB: 87.00 (-1.59), ISIS: 50.84 (-0.24), CMG: 666.37 (+2.12), EOG: 95.62 (-1.94), HAWK: 37.10 (-0.10), SHW: 237.56 (-0.54), VZ: 50.87 (+0.05), DOW: 49.20 (-0.70), REGN: 396.73 (-4.38), KELYA: 15.31 (-0.33), CBS: 52.02 (+0.45)

'The Walking Dead' dominates among young viewers
By DAVID BAUDER - AP - Tue Nov 11, 6:20PM CST
NEW YORK (AP) — "The Walking Dead" rules as television's most popular drama, but the Nielsen company's viewership totals only give a hint at the extent to which zombies rule.
DIS: 90.21 (+0.31), CMCSK: 53.82 (+0.42), CBS.A: 52.50 (+0.70), CMCSA: 54.07 (+0.47), CBS: 52.02 (+0.45)

Media firms seek FCC block
at Investor's Business Daily - Tue Nov 11, 5:31PM CST
CBS (CBS), 21st Century Fox (FOXA), Walt Disney (DIS) and several other media firms have asked the FCC to block disclosures of programming contracts, said Bloomberg. The companies claim that the disclosures, part of Comcast's (CMCSA) acquisition of...
FOXA: 34.80 (+0.16), DIS: 90.21 (+0.31), TWC: 140.07 (+3.59), CMCSA: 54.07 (+0.47), CBS: 52.02 (+0.45)

Nielsen's top programs for Nov. 3-9
By The Associated Press - AP - Tue Nov 11, 4:07PM CST
Prime-time viewership numbers compiled by Nielsen for Nov. 3-9. Listings include the week's ranking and viewership.
DIS: 90.21 (+0.31), CBS.A: 52.50 (+0.70), CBS: 52.02 (+0.45)

HBO, Warner Bros. Seen Growing Time Warner's EPS
at Investor's Business Daily - Tue Nov 11, 12:23PM CST
Time Warner (TWX) shares climbed on the stock market today after Goldman Sachs said the company has EPS growth opportunities ahead with HBO, Warner Bros. and its low advertising exposure. The media and entertainment giant was upgraded Tuesday to...
NFLX: 378.15 (-5.71), AMZN: 314.63 (+3.12), LGF: 35.25 (+0.86), SNE: 20.38 (-0.25), CMCSA: 54.07 (+0.47), CBS: 52.02 (+0.45), TWX: 78.50 (+0.82)

Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
AES: 13.61 (+0.17), AEM: 23.81 (+0.05), COHR: 58.39 (-0.49), ASEI: 43.49 (-1.28), CBS: 52.02 (+0.45)

TV programmers lose battle with FCC over contract access
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:24AM CST

AMCX: 60.66 (-0.74), FOXA: 34.80 (+0.16), DIS: 90.22 (+0.32), CMCSA: 54.07 (+0.47), SNI: 73.23 (-0.27), VIAB: 72.08 (+2.83), CRWN: 3.42 (-0.03), TWX: 78.50 (+0.82), CBS: 52.02 (+0.45)


CBS' Logan quarantined after Ebola report
By DAVID BAUDER - AP - Tue Nov 11, 5:48AM CST
NEW YORK (AP) — Lara Logan of CBS News is being quarantined in a South Africa hotel for three weeks as a precaution after visiting an American-run hospital treating Ebola patients in Liberia for a "60 Minutes" report that aired Sunday.
CBS.A: 52.50 (+0.70), CBS: 52.02 (+0.45)

Will CBS Corp Benefit from Streaming News Service? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 2:32PM CST
As number of cord cutters increase, media houses are making a frantic effort to go over-the-top with their content and CBS Corporation (CBS) is no exception.
FOXA: 34.80 (+0.16), DIS: 90.22 (+0.32), TWX: 78.50 (+0.82), CBS: 52.02 (+0.45)

Signs Of Bottoming At CBS
Steve Birenberg, CFA - at Seeking Alpha - Mon Nov 10, 2:09PM CST
CBS Corporation (NYSE: CBS ) reported third quarter results in line with or very slightly ahead of recently lowered Wall Street estimates. CBS shares have performed quite poorly this year, down almost 20%, as earnings have steadily fallen due to...
CBS: 52.02 (+0.45)

CBS Corporation Looks Attractive After Solid Q3 Earnings
Adam Levine-Weinberg, The Motley Fool - Motley Fool - Mon Nov 10, 1:05PM CST
Last week, CBS Corporation reported Q3 earnings. The company posted adjusted EPS of $0.74: representing a solid -- though not spectacular -- 6% year-over-year increase. CBS has experienced choppy earnings in 2014 compared to the explosive growth...
CBS: 52.02 (+0.45)

Next Resistance Level for CBS (CBS) is $52.22
Comtex SmarTrend(R) - Mon Nov 10, 10:04AM CST
Shares of CBS (NYSE:CBS) have bullishly opened above the pivot of $51.34 today and have reached the first resistance level of $51.76. Should the shares continue to rise, the resistance pivots of $52.22 and $53.10 will be of interest.
CBS: 52.02 (+0.45)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sarepta Under Scrutiny: KSF's Investigation Deepens

Updated Category News Views 3

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...

Continue Reading
Cyngn: A Deep Dive into Its Robust 24-Patent Portfolio

Updated Category News Views 4

Cyngn's Growing Patent Portfolio: A Robust Defense Ah, Cyngn Inc., the hotshot in AI-powered autonomous vehicle tech, is flexing its muscles with a solid 24-patent stash. We're talking about a company that's not messing around, racking these up since they decided to dive head-first into solving the brain-busting problems of the industrial sector. Their strategy? Build and...

Continue Reading
New Concierge Pediatric Care at Weill Cornell Launches

Updated Category News Views 3

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Continue Reading
Postal Service Defends New Rule Amid Speculation

Updated Category News Views 3

USPS Navigates Election Mail Controversies The U.S. Postal Service has found itself in the eye of a political storm, thanks to the latest Federal Ballot Mail Rule. Led by Postmaster General David Steiner, the USPS is setting the record straight amidst swirling misinformation and skepticism about its recent actions. This is not just a postal service under scrutiny—it's a...

Continue Reading
Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Updated Category News Views 6

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

Continue Reading
BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

Updated Category News Views 1

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

Continue Reading
S&P 500 Shuffle: Bloom, Illumina, Everpure Join Frenzy

Updated Category News Views 5

Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...

Continue Reading
TrailBlazer Magazine Snags a Tribune for In-House Design

Updated Category News Views 4

Who Knew? Design Awards Aren't Just for Pretty Pictures TrailBlazer Magazine gets a pat on the back from GDUSA's 2026 Inhouse Design Awards, a nod to top-notch design work. With over 4,000 entries across the board, getting into the top 10 percent is like finding a steakhouse with zero line on a Friday night. Not exactly common, right? Design Worth Cheering For The winning...

Continue Reading
MMRO Achieves URAC AI Accreditation, Ensures Compliance

Updated Category News Views 4

A Milestone in Healthcare AI: MMRO's New Accreditation When AI in healthcare gets an official nod from the big guys like URAC, it's a significant moment. We're talking about Managed Medical Review Organization, Inc. (MMRO), a firm that's just earned the URAC Artificial Intelligence in Health Care Accreditation. Now, this isn't just some rubber stamp; it's a testament to...

Continue Reading
Dimerix Locks Down A$34M Loan: No Shareholder Dilution

Updated Category News Views 2

Dimerix Grabs Non-Dilutive Funds amid Kidney Trials Here we go with Dimerix's latest move, folks. They roped in A$34 million through a cozy get-together with lenders from Australia and the U.S. What's the kicker? This cash won't touch shareholder equity. So, breathe easy, investors. It's a rare feat to pull off non-dilutive funds these days, especially in the biopharma...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming the Narcolepsy Market: Innovations Ahead

Updated Category News Views 166

The Evolving Landscape of the Narcolepsy Market The narcolepsy market is undergoing significant changes as it shifts from merely managing symptoms to developing targeted therapies that tackle the root causes of the disorder. Traditionally, treatments focused on alleviating symptoms, but advancements now emphasize addressing the underlying neurochemical issues, primarily...

Continue Reading
UBS Analysts Share Insights on China Stocks Strategies

Updated Category News Views 242

UBS Analysts Offer Insights on China's Equity Market In a recent discussion, UBS strategists have expressed a level of caution regarding China's equity market as they look into the evolving landscape of 2025. It's noted that local A-share investors appear hesitant to seize buying opportunities, influenced by a myriad of factors that create uncertainty in the market....

Continue Reading
Palisade Bio's Special Meeting Cancellation: What You Need to Know

Updated Category News Views 133

Palisade Bio Cancels Special Meeting of Stockholders Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company making strides in developing innovative treatments for autoimmune, inflammatory, and fibrotic diseases. Recently, the company announced an important decision regarding its special meeting of stockholders. The special meeting, originally...

Continue Reading
Vivendi Reports Impressive 4.5% Revenue Growth in 2024

Updated Category News Views 123

Remarkable Revenue Growth for Vivendi Vivendi has announced an impressive increase in its revenues for the first nine months of 2024, emphasizing strong growth across its core business sectors. The company reported a revenue increase of 4.5% at constant currency and perimeter, compared to the same period in the previous year. This growth showcases the resilience and...

Continue Reading
Revolution in Home Renovation Arrives with Spray-Net Franchise

Updated Category News Views 226

Fresh Approach to Home Makeovers Home remodeling isn’t just about slapping on a new coat of paint anymore. In February 2026, Spray-Net is gearing up to launch in Allen, Texas, shaking things up in the renovation game. This venture represents a leap forward—not only for franchise growth but for homeowners who are sick and tired of traditional, drawn-out renovations....

Continue Reading